“Pilavapadin, an oral, non-opioid, AAK1 inhibitor for diabetic peripheral neuropathic pain (DPNP): results from a Phase 2b, dose-ranging, randomized, placebo-controlled, multicenter study” was ...

However, prevalence was found to plateau over time, suggesting neuropathic pain may be isolated or intermittent events in some patients with type 1 diabetes. “The features and burden of neuropathic ...

(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Neuropathic Pain pipeline constitutes 10+ key companies continuously working towards ...

THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific ...

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, announced today that it has been selected by Lexicon ...

NEW YORK (Reuters Health) - Duloxetine appears to be a safe and effective treatment for diabetes-related pain caused by damage to the peripheral nervous system, according to a report in the journal ...

Selective serotonin reuptake inhibitors (SSRIs) and other types of antidepressents have demonstrated varying efficacy for diabetic neuropathy, and have generally been found to be less effective than ...

Presenters: Belinda Hardin, PharmD, BCPS, Senior Director, Medical Communications, and Suma Gopinathan, M.S, Ph.D., Senior Vice President, Discovery, Lexicon Pharmaceuticals Diabetic neuropathy is a ...

AUSTIN, TX—Duloxetine, pregabalin, and duloxetine + gabapentin were found to be safe and tolerable for the treatment of diabetic peripheral neuropathic pain, according to results presented today at ...